Mankind Pharma Ltd
As of 20 Nov 2026, Mankind Pharma is in Stage 2, the uptrend phase, now in week 2 (since 13 Nov 2026). It closed at ₹2,665, at its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. More about the company
Pro read
ProOur read
Setup score
RS rank
Edge
MANKIND is 2 weeks into its Stage 2 advance, 9% above its 50-day average and at its 52-week high. The first weeks are when a move is least proven; a close back below its 50-day average would be the first sign of trouble.
Its relative strength is 78 of 99, above the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.
Stocks with a similar setup at this point in their move ran 0.7 points ahead of the average stock over the next 30 sessions on average, after costs, and their typical best close within 60 sessions was 16% above entry.
The trend read holds while it stays in Stage 2. A close below ₹2,443, its 50-day average, would put it at rest; ₹2,135, 20% under its 52-week high of ₹2,668, is where a trailing stop would sit.
Setup-score rank among Stage 2 peers: #16 of 50 in Pharmaceuticals · #21 of 61 in Health Care
Is MANKIND early, or has it already run? Pro answers that for every NSE stock, after every close.
MANKIND among Pharmaceuticals49th of 118 by relative strength
All 118 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | BLISSGVS | Stage 2 · wk 49 | 99 | +4.6% |
| 2 | KPL | Stage 2 · wk 44 | 99 | +20.5% |
| 3 | FREDUN | Stage 2 · wk 33 | 98 | +24.0% |
| 4 | VENUSREM | Stage 3 · wk 10 | 98 | −1.5% |
| 5 | RUBICON | Stage 3 · wk 4 | 98 | +18.7% |
| 6 | SAKAR | Stage 2 · wk 55 | 98 | +13.1% |
| 7 | BAFNAPH | Stage 2 · wk 23 | 98 | +1.9% |
| 8 | INDSWFTLAB | Stage 2 · wk 23 | 98 | −7.4% |
| …49 | MANKIND | Stage 2 · wk 2 | 78 | +16.6% |
Mutual fund holdings
Held by 142 mutual funds in portfolios to October 2026: 84 active funds and 58 index funds and ETFs.
In October, among active funds: 18 increased, 12 opened a new position, 9 reduced and 5 exited.
All 142 funds, the 5 that exited, and what each did in October
Mutual funds holding MANKIND: the ten largest and the month’s moves →
Mankind Pharma: quick answers
What stage is Mankind Pharma in?
As of 20 Nov 2026, Mankind Pharma (MANKIND) is in Stage 2, the uptrend phase. It entered Stage 2 on 13 Nov 2026 and is in week 2. What the four stages mean
Is Mankind Pharma in an uptrend?
Yes. Mankind Pharma is in a Stage 2 uptrend. It trades 13.7% above its 200-day average, which is rising.
How far is Mankind Pharma from its 52-week high?
Mankind Pharma closed at ₹2,665 on 20 Nov 2026, at its 52-week high. Its 52-week low is ₹1,927.
How has Mankind Pharma performed over the past year?
As of 20 Nov 2026, Mankind Pharma is up 18.1% over the past year and up 21.3% so far in 2026.
Is Mankind Pharma in F&O, and what is its lot size?
Yes. Mankind Pharma (MANKIND) trades in NSE's F&O segment, with a near-month lot size of 250 shares as of 20 Nov 2026. NSE revises lot sizes a few times a year; ours are reloaded from the exchange's list after every close.
Which sector and industry is Mankind Pharma in?
Mankind Pharma is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals
About this companyHealth Care· Pharmaceuticals
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.